SPI Pharma: From Decades of Alum Leadership to Next-Generation Vaccine Solutions
For more than two decades, SPI Pharma has been a trusted supplier of high-quality aluminum hydroxide vaccine adjuvants. Building on more than 70 years of expertise in aluminum hydroxide chemistry, the company has supplied alum-based adjuvants used in commercial vaccines worldwide. Although historically stronger in the veterinary market through its VAC range, SPI Pharma is now making a deliberate and expansive push into human health, investing in technology, capacity, and strategic partnerships to deliver a broader, more sophisticated adjuvant toolbox.
Aluminum hydroxide remains the most widely used and studied adjuvant chemistry globally, prized for its safety profile, antigen adsorption performance, and regulatory familiarity. SPI Pharma’s long manufacturing experience has given it deep process knowledge around consistency in morphology, particle size, protein adsorption capacity, and compliance withmonograph standards. That foundation is now being leveraged for human applications under the Valens™ brand while the VAC portfolio continues to serve animal health with expanded grade options.
Strategic Investments and Global Partnerships
Over the past two to three years, SPI Pharma has accelerated its vaccine ambitions through targeted investments and collaborations with specialized partners:
In 2023, SPI Pharma entered a strategic partnership and investment agreement with Q-Vant Biosciences. The collaboration expands commercial-scale GMP manufacturing of high-purity saponin adjuvants using Q-Vant’s proprietary, 100% sustainable Q-SAP™ technology, which sources saponins from renewable biomass. The commercial agreement gives SPI Pharma global reach for these materials. Quillaja saponin-based adjuvants such as QS-21 are considered a gold-standard component in multiple approved and pipeline human vaccines, including those for shingles, malaria, and RSV. SPI Pharma now offers Valens™ QS-21 GH and high-purity Valens™ QS-21 XP grades for human use, alongside VAC Saponin for veterinary applications.
In 2024, SPI Pharma partnered with Inimmune Corp.
To develop and commercialize advanced adjuvant systems. The collaboration combines Inimmune’s expertise in innate immune modulators with SPI Pharma’s manufacturing scale and commercial infrastructure. Key systems now advancing under the Valens™ name include:
Valens™ T4Q
A liposomal adjuvant system pairing Inimmune’s fully synthetic TLR4 agonist (INI-2002) with QS-21. It is designed to elicit robust Th1-biased responses comparable to established MPLA + QS-21 systems, with formulations aimed at improved stability and accessibility.
Valens™ T4AH
An adjuvant system in which INI-2002 is adsorbed onto aluminum hydroxide. It combines classical alum-mediated antigen presentation with targeted TLR4 activation to produce stronger and more durable antibody and cellular immune responses than alum alone.
Valens™ T4SE
A squalene-based oil-in-water emulsion combined with INI-2002, a fully synthetic TLR4 agonist. In preclinical studies, adding INI-2002 to the squalene emulsion significantly improved immune responses, driving strong antibody quality and a balanced cellular response. Because its composition is similar to adjuvant systems already approved for human influenza vaccines, it has potential for future use.
The Valens™ Brand and Human Health Expansion
August 2025, SPI Pharma launched the Valens™ portfolio brand (from the Latin for “strong, vigorous, and healthy”) to group its vaccine adjuvants, parenteral excipients, and related materials for the biologics and human vaccine markets. The brand differentiates these higher-value offerings from the company’s broader pharmaceutical and consumer health portfolio while signaling a focused growth strategy.
Under Valens™ AH, SPI Pharma has expanded its aluminum hydroxide grades specifically for human vaccines (including concentrations such as AH 1.5, AH 2.0, and AH 3.0). These grades offer formulation flexibility—different alumconcentrations and particle-size—while maintaining the well-characterized adsorption properties and scalable cGMP manufacturing that customers expect.. The company is also investing in manufacturing capabilities, including upgrades at its long-standing French site in Septèmes-les-Vallons, to meet human-vaccine quality standards and increase capacity.
SPI Pharma positions these developments as part of a broader mission: making advanced, stable, and supply-secure adjuvants more accessible to vaccine developers worldwide. By combining its own alum manufacturing expertise with partner technologies in sustainable saponins and synthetic TLR4 agonist, the company aims to offer both single components and ready-to-use systems that can be tailored to specific immunogenicity needs—from traditional antibody-focused responses to more balanced cellular immunity.
Looking Ahead
As global vaccine pipelines turn to more challenging diseases, reliable and innovative adjuvant supply becomes critical. SPI Pharma’s recent investments, the Valens™ brand architecture, and partnerships with companies recognized for saponin sustainability and innate immune science mark a clear strategic expansion into human health. With manufacturing and commercial teams on multiple continents and a track record of supporting commercial vaccine production, the company positions itself as a collaborative partner that helps developers move from formulation challenges to scalable, high-quality solutions.
SPI Pharma’s shift from trusted alum supplier to broader next-generation adjuvant provider is a deliberate strategy: it pairs established excipient expertise with targeted technology partnerships and focused investment. The result gives vaccine innovators more options and a dependable route from formulation to scale, in support of better patient outcomes.